Healthcare intelligence needs a verification layer. Be the team that built it first. Four independent agents audit every brief and return one consensus verdict: PROCEED, DELAY, or KILL — before your organization is exposed.
One system, described at two altitudes. The four adversarial agents are the audit — PROCEED, DELAY, or KILL on any single decision. Cortex is the engine those agents run on, and the six modules below are what keep that audit continuous instead of one-time.
When your VP of Strategy leaves, everything they knew leaves with them. Company Memory captures institutional knowledge, strategic context, and R&D intelligence — and keeps it alive through every transition.
Your competitors filed a patent yesterday. A clinical trial in your space failed last week. An FDA guidance shifted your regulatory timeline. You found out about none of them. Cortex is already watching.
FDA guidance changes don't wait for your quarterly review. They hit and your filing timeline shifts before anyone on your team reads the announcement. This module is designed to surface guidance changes before timelines move.
By the time a market narrative shift appears in analyst reports, the positioning window is closed. This layer detects belief divergence while there is still time to act on it.
Your board asks a question. Your team scrambles for two weeks to assemble an answer from scattered sources. The Briefing Engine delivers decision-ready intelligence on your cadence — before anyone has to ask.
Every query you run on a shared AI platform trains someone else's model. Your strategic questions become another company's dataset. This workspace is yours alone. Isolated. Private. Non-negotiable.
$12–15B repricing inside the 2025–2026 CMS LCD cycle. 86 source-cited signals across PubMed, ClinicalTrials.gov, and SEC. 30 companies under continuous SCOUT monitoring. Refreshed live.
96 source-cited signals. 49 companies under continuous SCOUT monitoring. 18% Saudi diabetes prevalence — Vision 2030 procurement live. The platform that turns indication intelligence into adversarial verification.
146 source-cited signals including 30 SEER cancer-site stat facts. 50 companies under continuous SCOUT monitoring. Population epidemiology layered on adversarial verification — only oncology pipeline carries this.
1,710 source-cited signals across PubMed, ClinicalTrials.gov, FDA, and SEC. 50 companies under continuous SCOUT monitoring across the heart-failure, AFib, and cardiometabolic frontier. Sovereign GCC procurement live.
1,692 source-cited signals. 40 companies under continuous SCOUT monitoring across the CKD, ESRD, dialysis, and transplant frontier. The DKD intersection cross-tagged with the diabetes pipeline. Five sovereign anchors.
500 source-cited signals. 50 companies under continuous SCOUT monitoring across the GLP-1, GIP, and MASH frontier. Manufacturing-capacity leading indicators (Catalent, Halozyme). Five sovereign anchors.
Curated digest of strategic movements, regulatory shifts, and decision-ready intelligence tailored to leadership priorities.
Side-by-side analysis of competitive assets, development timelines, and strategic positioning across your market.
Alerts when market consensus begins shifting from established belief, signaling emerging opportunity or risk.
AimwellBio is decision-support infrastructure. It is not medical advice, regulatory guidance, legal counsel, or an investment recommendation. All outputs are designed for review by qualified professionals before use in clinical, regulatory, legal, or investment workflows.
System architecture
AimwellBio is the company. The Platform is the environment the validation layer runs in. Each component below performs one role in that path — nothing is a standalone tool bolted on beside the others.
A brief, memo or claim enters through Signal Ingestion. Evidence is drawn from regulatory filings, scientific literature, market signals and the FHIN federated contributor network.
Cortex carries the analysis across six modules — Signal Ingestion, Memory, Regulatory, Market Belief, Executive Briefing and Private Intelligence — operating as one verification layer rather than six separate tools.
Four independent agents audit the same material in parallel along distinct axes: regulatory, market, scientific and competitive. None defers to another. Disagreement is retained as signal.
The four positions reconcile into one verdict — PROCEED, DELAY or KILL — carrying a confidence score and full source traceability. Claims that cannot resolve to a source are gated rather than passed.
Output reaches the decision-maker through the Executive Briefing module or on demand via AIMN:VERDICT. Access tier determines scope of delivery, not the rigour of the audit.
Primary buyer
The person accountable for the decision: biopharma and enterprise biotech teams, investors and capital allocators, sovereign health ministries, and credentialed individual practitioners.
Use cases
Auditing a brief before a regulatory submission, a licence, a board paper or a capital commitment. Monitoring a category on a scheduled refresh rather than ad hoc.
Inputs
Briefs, memos and claims, plus the evidence base behind them: regulatory filings, scientific and clinical literature, market and competitive signals.
Outputs
A source-traced verdict with a confidence score, the four independent positions behind it, and a record of what was checked — a decision object, not a summary.
Differentiation
A general-purpose model generates an answer. This audits one, through four independent reviewers, against a methodology that is published rather than proprietary.
Deployment & availability
Five steps: assess, configure, ingest, activate, then scheduled refresh. Security and compliance posture is documented at /security.
AimwellBio, explained
What each component is and the role it performs in the validation layer.
AIMN is the ticker symbol for Aimwell Partners Inc., the company that operates AimwellBio. It also prefixes the product lines built on the validation layer — AIMN:VERDICT, the adversarial intelligence engine that returns on-demand entity verdicts, and AIMN:ATLAS. The company and the product namespace share the symbol.
Cortex is the intelligence operating system underneath the platform — six modules working as one verification layer: Signal Ingestion, Memory, Regulatory, Market Belief, Executive Briefing, and Private Intelligence. Every Cortex output carries a confidence score and is source-traced back to the evidence behind it.
FHIN is the Federated Health Intelligence Network — the contributor and verification layer behind the platform. Credentialed professionals participate in it, and their verified participation is what distinguishes a federated network from an unsourced aggregate. A founding contributor cohort is open.
These are access tiers, not separate products. Observer is free for credentialed professionals; Member, Signal, Shield and Command provide progressively broader access to verdicts, monitoring and private intelligence. All tiers operate on the same validation layer — the tier determines scope of access, not the rigour of the audit.
A verdict is the output of the validation layer: PROCEED, DELAY, or KILL, issued with a confidence score and source traceability. It is the reconciliation of four independent audits rather than a single model's opinion, and it is deliberately a decision object rather than a summary — something a person can attach to the decision they are accountable for.
A general-purpose model generates an answer; AimwellBio audits one. The unit of output is a source-traced verdict from four independent reviewers, not a fluent response from a single system. The methodology is published rather than proprietary, and disagreement between reviewers is preserved rather than smoothed into a confident-sounding paragraph.
Observer access is free for credentialed professionals. Methodology published as the Adversarial Validation Standard, v1.0 (2026-09). Security and compliance posture: /security.